![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: F2 |
Gene summary for F2 |
![]() |
Gene information | Species | Human | Gene symbol | F2 | Gene ID | 2147 |
Gene name | coagulation factor II, thrombin | |
Gene Alias | PT | |
Cytomap | 11p11.2 | |
Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | P00734 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2147 | F2 | NAFLD1 | Human | Liver | NAFLD | 9.89e-14 | 7.90e-01 | -0.04 |
2147 | F2 | S42 | Human | Liver | HCC | 2.13e-05 | 8.38e-01 | -0.0103 |
2147 | F2 | S43 | Human | Liver | Cirrhotic | 2.49e-07 | 1.05e-01 | -0.0187 |
2147 | F2 | HCC1_Meng | Human | Liver | HCC | 1.04e-80 | 9.88e-01 | 0.0246 |
2147 | F2 | HCC2_Meng | Human | Liver | HCC | 4.95e-09 | -2.59e-01 | 0.0107 |
2147 | F2 | HCC1 | Human | Liver | HCC | 1.98e-25 | 5.00e+00 | 0.5336 |
2147 | F2 | HCC2 | Human | Liver | HCC | 3.09e-51 | 6.34e+00 | 0.5341 |
2147 | F2 | HCC5 | Human | Liver | HCC | 8.60e-04 | 3.95e+00 | 0.4932 |
2147 | F2 | Pt13.a | Human | Liver | HCC | 5.10e-04 | 2.62e-01 | 0.021 |
2147 | F2 | Pt13.b | Human | Liver | HCC | 1.18e-26 | 3.65e-01 | 0.0251 |
2147 | F2 | Pt14.a | Human | Liver | HCC | 5.50e-13 | 8.94e-01 | 0.0169 |
2147 | F2 | Pt14.b | Human | Liver | HCC | 5.18e-12 | 6.44e-01 | 0.018 |
2147 | F2 | Pt14.d | Human | Liver | HCC | 2.29e-05 | 4.93e-01 | 0.0143 |
2147 | F2 | S014 | Human | Liver | HCC | 1.99e-50 | 3.29e+00 | 0.2254 |
2147 | F2 | S015 | Human | Liver | HCC | 3.05e-52 | 3.52e+00 | 0.2375 |
2147 | F2 | S016 | Human | Liver | HCC | 3.24e-50 | 3.13e+00 | 0.2243 |
2147 | F2 | S027 | Human | Liver | HCC | 1.75e-27 | 2.39e+00 | 0.2446 |
2147 | F2 | S028 | Human | Liver | HCC | 6.56e-57 | 2.58e+00 | 0.2503 |
2147 | F2 | S029 | Human | Liver | HCC | 5.93e-59 | 3.06e+00 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00021819 | Breast | Precancer | cytoplasmic translation | 80/1080 | 148/18723 | 1.59e-59 | 8.54e-56 | 80 |
GO:00226139 | Breast | Precancer | ribonucleoprotein complex biogenesis | 79/1080 | 463/18723 | 2.11e-18 | 1.03e-15 | 79 |
GO:00069799 | Breast | Precancer | response to oxidative stress | 70/1080 | 446/18723 | 1.59e-14 | 4.26e-12 | 70 |
GO:00064578 | Breast | Precancer | protein folding | 43/1080 | 212/18723 | 3.48e-13 | 7.45e-11 | 43 |
GO:00422549 | Breast | Precancer | ribosome biogenesis | 52/1080 | 299/18723 | 7.35e-13 | 1.51e-10 | 52 |
GO:00083809 | Breast | Precancer | RNA splicing | 65/1080 | 434/18723 | 1.27e-12 | 2.53e-10 | 65 |
GO:00434849 | Breast | Precancer | regulation of RNA splicing | 34/1080 | 148/18723 | 2.66e-12 | 4.75e-10 | 34 |
GO:00064179 | Breast | Precancer | regulation of translation | 67/1080 | 468/18723 | 4.71e-12 | 7.64e-10 | 67 |
GO:00457279 | Breast | Precancer | positive regulation of translation | 32/1080 | 136/18723 | 5.89e-12 | 9.27e-10 | 32 |
GO:00003759 | Breast | Precancer | RNA splicing, via transesterification reactions | 52/1080 | 324/18723 | 1.74e-11 | 2.22e-09 | 52 |
GO:00003779 | Breast | Precancer | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 51/1080 | 320/18723 | 3.55e-11 | 4.04e-09 | 51 |
GO:00003989 | Breast | Precancer | mRNA splicing, via spliceosome | 51/1080 | 320/18723 | 3.55e-11 | 4.04e-09 | 51 |
GO:00342509 | Breast | Precancer | positive regulation of cellular amide metabolic process | 33/1080 | 162/18723 | 1.72e-10 | 1.77e-08 | 33 |
GO:00422749 | Breast | Precancer | ribosomal small subunit biogenesis | 21/1080 | 73/18723 | 4.84e-10 | 4.39e-08 | 21 |
GO:00064588 | Breast | Precancer | 'de novo' protein folding | 16/1080 | 43/18723 | 8.14e-10 | 6.92e-08 | 16 |
GO:00003029 | Breast | Precancer | response to reactive oxygen species | 38/1080 | 222/18723 | 1.47e-09 | 1.23e-07 | 38 |
GO:00610778 | Breast | Precancer | chaperone-mediated protein folding | 19/1080 | 67/18723 | 4.22e-09 | 3.28e-07 | 19 |
GO:00510848 | Breast | Precancer | 'de novo' posttranslational protein folding | 14/1080 | 39/18723 | 1.61e-08 | 1.12e-06 | 14 |
GO:00510858 | Breast | Precancer | chaperone cofactor-dependent protein refolding | 13/1080 | 34/18723 | 2.17e-08 | 1.47e-06 | 13 |
GO:00359669 | Breast | Precancer | response to topologically incorrect protein | 29/1080 | 159/18723 | 3.00e-08 | 1.89e-06 | 29 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517114 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa04610 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0513014 | Liver | NAFLD | Pathogenic Escherichia coli infection | 45/1043 | 197/8465 | 2.31e-05 | 6.88e-04 | 5.54e-04 | 45 |
hsa0481010 | Liver | NAFLD | Regulation of actin cytoskeleton | 50/1043 | 229/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 50 |
hsa0517115 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa046101 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0513015 | Liver | NAFLD | Pathogenic Escherichia coli infection | 45/1043 | 197/8465 | 2.31e-05 | 6.88e-04 | 5.54e-04 | 45 |
hsa0481011 | Liver | NAFLD | Regulation of actin cytoskeleton | 50/1043 | 229/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 50 |
hsa0517122 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0481021 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0513022 | Liver | Cirrhotic | Pathogenic Escherichia coli infection | 88/2530 | 197/8465 | 6.48e-06 | 6.24e-05 | 3.84e-05 | 88 |
hsa0517132 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0481031 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0513032 | Liver | Cirrhotic | Pathogenic Escherichia coli infection | 88/2530 | 197/8465 | 6.48e-06 | 6.24e-05 | 3.84e-05 | 88 |
hsa0517142 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa0513042 | Liver | HCC | Pathogenic Escherichia coli infection | 129/4020 | 197/8465 | 2.02e-07 | 2.50e-06 | 1.39e-06 | 129 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0481041 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
GZMA | F2R | GZMA_F2R | PARs | Breast | ADJ |
GZMA | F2RL2 | GZMA_F2RL2 | PARs | Breast | ADJ |
GZMA | F2R | GZMA_F2R | PARs | Breast | DCIS |
CTSG | F2RL3 | CTSG_F2RL3 | PARs | Breast | Healthy |
GZMA | F2RL3 | GZMA_F2RL3 | PARs | Breast | Healthy |
GZMA | F2R | GZMA_F2R | PARs | Breast | IDC |
CTSG | F2R | CTSG_F2R | PARs | Cervix | ADJ |
GZMA | F2R | GZMA_F2R | PARs | Cervix | ADJ |
PRSS3 | F2R | PRSS3_F2R | PARs | Cervix | CC |
CTSG | F2R | CTSG_F2R | PARs | Cervix | CC |
GZMA | F2R | GZMA_F2R | PARs | Cervix | CC |
GZMA | F2R | GZMA_F2R | PARs | Cervix | Healthy |
CTSG | F2R | CTSG_F2R | PARs | Cervix | Precancer |
GZMA | F2R | GZMA_F2R | PARs | Cervix | Precancer |
PRSS3 | F2R | PRSS3_F2R | PARs | CRC | AD |
CTSG | F2R | CTSG_F2R | PARs | CRC | AD |
GZMA | F2R | GZMA_F2R | PARs | CRC | AD |
PRSS3 | F2RL3 | PRSS3_F2RL3 | PARs | CRC | AD |
CTSG | F2RL3 | CTSG_F2RL3 | PARs | CRC | AD |
GZMA | F2RL3 | GZMA_F2RL3 | PARs | CRC | AD |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
F2 | SNV | Missense_Mutation | novel | c.1379A>G | p.Asp460Gly | p.D460G | P00734 | protein_coding | deleterious(0.01) | probably_damaging(0.993) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
F2 | SNV | Missense_Mutation | c.866N>G | p.Asn289Ser | p.N289S | P00734 | protein_coding | tolerated(0.44) | benign(0.186) | TCGA-BC-A10U-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
F2 | SNV | Missense_Mutation | novel | c.430N>C | p.Ser144Pro | p.S144P | P00734 | protein_coding | tolerated(0.55) | benign(0.003) | TCGA-DD-AADP-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
F2 | SNV | Missense_Mutation | novel | c.1792N>T | p.Gly598Trp | p.G598W | P00734 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-05-4396-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
F2 | SNV | Missense_Mutation | c.1312N>T | p.Ile438Phe | p.I438F | P00734 | protein_coding | tolerated(0.1) | benign(0.006) | TCGA-44-7670-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | |
F2 | SNV | Missense_Mutation | c.22N>A | p.Gln8Lys | p.Q8K | P00734 | protein_coding | tolerated_low_confidence(0.33) | benign(0.006) | TCGA-50-5933-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | carboplatin | CR | |
F2 | SNV | Missense_Mutation | novel | c.1087N>T | p.Arg363Cys | p.R363C | P00734 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-55-8506-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
F2 | SNV | Missense_Mutation | novel | c.1045G>T | p.Asp349Tyr | p.D349Y | P00734 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-55-A4DG-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
F2 | SNV | Missense_Mutation | c.388N>A | p.Gln130Lys | p.Q130K | P00734 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-64-5778-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Targeted Molecular therapy | tarceva | PD | |
F2 | SNV | Missense_Mutation | c.328N>A | p.Glu110Lys | p.E110K | P00734 | protein_coding | tolerated(0.69) | benign(0.01) | TCGA-91-6840-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | Anisindione | ANISINDIONE | ||
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | LEPIRUDIN | LEPIRUDIN | ||
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | ATryn antithrombin | 24391399 | ||
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | (-)-EPICATECHIN | (-)-EPICATECHIN | ||
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | hormonal contraceptives for systemic use | 15208046,28750087,12069454,16769590 | ||
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | Odiparcil | ODIPARCIL | ||
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | QUERCETIN | QUERCETIN | ||
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | AZD-0837 | ATECEGATRAN METOXIL | ||
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | Hirudin | |||
2147 | F2 | PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, GROWTH FACTOR, DRUGGABLE GENOME, ENZYME | inhibitor | 178102998 | DABIGATRAN |
Page: 1 2 3 4 5 6 7 8 9 |